Consumers Warned Not To Use Erectile Dysfunction Treatment Oyster Plus

Erectile Dysfunction Treatment Oyster Plus
Health Canada is advising consumers not to use Oyster Plus was an approved sexual enhancement/erectile dysfunction product in Malaysia due to concerns about possible side-effects.
The Malaysian Ministry of Health cancelled the registration of the product Oyster Plus due to the presence of tadalafil, a prescription drug used for the treatment of erectile dysfunction that should only be taken under the guidance of a health professional.
Possible Side Effects � � � � � �
Unsupervised use of tadalafil by patients with heart disease can result in serious cardiovascular side-effects such as sudden cardiac death, heart attack, stroke, hypertension, chest pain and abnormal heartbeat.
Additionally, use of tadalafil may be associated with other side-effects including temporary vision loss, seizure, prolonged erection, headache, flushing, nasal congestion and abdominal pain. Tadalafil should not be used by individuals taking any type of nitrate drug (e.g., nitroglycerine) due to the risk of developing potentially life-threatening low blood pressure.

Consumers Advised Not To Use The Following Products For Treatment Of Erectile Dysfunction

Health Canada is advising consumers not to use the following product for treatment of erectile dysfunction due to concerns about possible side-effects.
Product Names are Power 58 Extra, Platinum Power 58 Extra, Enhanix New Extra Men's Formula, Valentino, King Power Oral Solution, and Stretch Up Capsules.
The products contain sildenafil and vardenafil analogues.
Sildenafil and vardenafil are prescription medications indicated for treatment of erectile dysfunction. They should only be used under the supervision of a health care professional.
Possible Side Effects associated with both sildenafil citrate and vardenafil hydrochloride include headache, flushing, gastrointestinal disorders, penile tissue damage, visual disturbances, and inflammation of the mucous membrane of the nose.
Products containing sildenafil citrate or vardenafil hydrochloride should also not be used by anyone taking a nitrate medication, as the combination could lead to potentially life-threatening low blood pressure.

Men with Erectile Dysfunction Have Increased Risk for Cardiovascular Events

Erectile Dysfunction and Heart

Men with erectile dysfunction have a higher risk of subsequent cardiovascular events such as heart attack, stroke, and angina, according to a study in the December 21 issue of JAMA.
More than 10 million men in the United States are affected by erectile dysfunction (ED), with an estimated 100 million men affected worldwide, according to background information in the article. The risk of erectile dysfunction is related to many factors, including age, smoking, diabetes, heart disease, depression, and hypertension. Because cardiovascular disease and erectile dysfunction share etiologies as well as pathophysiology (endothelial dysfunction) and because of evidence that degree of erectile dysfunction correlates with severity of cardiovascular disease, it has been postulated that erectile dysfunction is a sentinel symptom in patients with cardiovascular disease.
Ian M. Thompson, M.D., of the University of Texas Health Science Center at San Antonio, and colleagues studied a group of men who were assessed for ED and subsequent cardiovascular disease over the course of 7 years. The study included men aged 55 years or older who were randomized to the placebo group (n = 9,457) in the Prostate Cancer Prevention Trial at 221 U.S. centers. Participants were evaluated every 3 months for cardiovascular disease and erectile dysfunction between 1994 and 2003. In analysis, factors at study entry taken into account included age, body mass index, blood pressure, serum lipids, diabetes, family history of heart attack, race, smoking history, current use of antihypertensive medication, physical activity, and quality of life.
Of the 9,457 men randomized to placebo, 8,063 (85 percent) had no cardiovascular disease at study entry; of these men, 3,816 (47 percent) had erectile dysfunction at study entry. Among the 4,247 men without erectile dysfunction at study entry, 2,420 men (57 percent) reported incident erectile dysfunction after 5 years. After adjustment, incident erectile dysfunction was associated with a 25 percent increased risk for subsequent cardiovascular events during study follow-up. For men with either incident or prevalent erectile dysfunction, the increased risk was 45 percent.
"Our analysis of men in the placebo group of this study demonstrates the substantial association between incident as well as prevalent erectile dysfunction and subsequent cardiovascular disease, including angina, myocardial infarction, stroke, and transient ischemic attack," the authors write.
"The implications of this study are substantial. With the availability of effective pharmacotherapy, an increasing number of men are seeking care for erectile dysfunction. It is estimated that more than 600,000 men aged 40 to 69 years in the United States develop erectile dysfunction annually. Our data suggest that the older men in this group have about a 2-fold greater risk of cardiovascular disease than [younger] men without erectile dysfunction. With 70 percent to 89 percent of sudden cardiac deaths occurring in men and with many men not having regular physical examinations, this analysis suggests that the initial presentation of a man with erectile dysfunction should prompt the evaluating physician to screen for standard cardiovascular risk factors and, as appropriate, initiate cardioprotective interventions," they write.